Connect with us

Entertainment

Pharma CEO squirms as Katie Porter exposes his price-gouging scheme with her trusty whiteboard Parents are struggling to explain the presidential debate to their children Global mayors are declaring their commitment to divest from fossil fuels and invest in a sustainable future After 16 years sober, Dax Shepard bravely announced a reset of his sobriety clock ‘Weird Al’ takes a rare foray into political humor with his hilarious new election song

Published

on

Americans spend about $1,200 a year on average for prescription drugs. That’s more than anywhere else in the world. Private insurers and government programs pick up the bulk of the costs which we then pay through higher taxes and insurance premiums.

A major reason why Americans pay so much more than other countries is that the U.S government isn’t allowed to negotiate drug prices with pharmaceutical companies.

To better understand the underlying reasons for these astronomical prices, the U.S. House of Representatives Oversight and Reform Committee held hearings on Wednesday with current and former executives of three major drug companies.


Democratic Representative Katie Porter from Orange County, California proved to be the star of the hearing for how she clearly explained how price gouging works using a whiteboard and the testimony of former Celgene CEO Mark Alles.

via Revlimid

Celgene launched a cancer drug called Revlimid in 2005 at a price of $215 per pill. After more than 20 price hikes, the drug now costs $763 per pill or $16,023 per month. According to Porter, the price increases have cost American taxpayers over $3 billion.

While drug companies commonly cite research and development costs as a reason for raising prices. An investigation found that the CEO repeatedly raised the price to help the company meet revenue goals.

The investigation also found the company was profiting from a drug that was developed using taxpayer funds. According to the investigation the company “relied heavily on taxpayer-funded academic research to develop Revlimid, and its internal pricing decisions appear to have been unrelated to past or future investment in research and development.”


Rep. Porter grills Big Pharma CEO for price gouging

www.youtube.com

Porter opened her questioning by remarking how Revlimid price increases seem to counter traditional economic logic.

“I’m curious, did the drug get substantially more effective in that time? Did cancer patients need fewer pills?” she asked. “How did you change the formula for the production of Revlimid to justify this price increase?”

Alles responded with a non-answer: “The indication changes are for subsets of different patients with disease.”

She then pushed him again, asking how the drug improved over the past seven years.

He admitted that the manufacturing for the pill was “the same.”

Porter then brilliantly related the price increase to the financial situation of her constituents. “So, to put that in perspective, you hiked the price by $500 when the average Orange County senior only has $528 left in their bank account after they’ve paid their basic monthly expenses,” Porter said.

While the CEO claimed that no one pays the list price, she asked about uninsured people. He said he could “imagine” that there were uninsured or underinsured people who have probably paid the list price.

via Katie Porter

Porter finished her presentation by tying the price increases to Alles’ paycheck. As CEO, Alles made $13 million a year, 360 times the average person on social security.

“Any increase in the price of Revlimid would also increase your bonus by increasing earnings. Isn’t that right Mr. Alles? she asked. “That was a part of the calculation of my compensation.” the CEO agreed.

Porter then showed how the CEO has made $500,000 over the past two years in bonuses by raising the price of the cancer drug.

“So to recap here: The drug didn’t get any better. The cancer patients didn’t get any better. You just got better at making money. You just refined your skills at price gouging!” she stated.

From Your Site Articles

Related Articles Around the Web

Continue Reading

Entertainment

Radhika Apte reveals real reason why she got married

Published

on

By

Radhika Apte needs no introduction to Kollywood fans after her appearance as Superstar Rajinikanth’s wife in ‘Kabali’ directed by Pa Ranjith.  The intense actress impressed with her performance of a meek girl to a mother of a grown-up and especially her reunion scene with Rajini took the audience on an emotional ride.

Radhika is happily married to her British boyfriend Benedict Taylor who is a singer and she shuttles between Mumbai and London to balance her personal and professional life.

Radhika Apte in her most recent interaction with Vikranth Massey on social media from London has admitted that she does not believe in the institution of marriage.  When asked why she got married the talented performer replied that it is easier for married people to get a British visa and that’s why she and her man opted for it in 2012.

Radhika is currently chilling with Taylor in their London home during the lockdown and will soon start filming her next English film ‘Noor Inayat Khan’ in which she plays a spy based on a true story.

Read More

Continue Reading

Entertainment

Jacqueline Fernandez shares picture of her being in ‘happy place’

Published

on

By

Actor Jacqueline Fernandez is working on a secret project where she found herself in a ‘happy place’. Taking it to Instagram on Sunday, the 35-year-old actor shared a picture dressed up like a traffic police officer as she is seen laughing her heart out.

“How was everyone’s Sunday?? Fun project coming up soon! #myhappyplace,” wrote Fernandez along with a picture where she is also seen holding a coffee mug. The ‘Kick’ actor also shared a few Instagram stories of her getting ready for the upcoming project.

Recently, the actor extended gratitude to her fans after the number of Instagram followers hit the 46 million mark.

Keep scrolling to read more news

Read More

Continue Reading

Entertainment

Why an ‘active’ approach to risk modelling is key to navigating markets today

Published

on

By

Whether investors are aiming for a cautious approach or a riskier investment profile with the potential for higher returns, Architas’ Blended Fund range is designed to match a range of investor risk appetites. And like many asset managers, Architas predominantly uses two approaches to define asset allocation within the five risk bands used in the Blended Range – strategic and tactical.

Whilst risk model provider EValue’s quantitative approach to asset allocation takes into account the long-term performance of different asset classes and the likely future performance given current valuations, along with long-term measures of volatility and correlations with other asset classes. Yet as with most systems of its kinds, EValue focuses on the long term; it is unable to analyse short-term market movements and fluctuations. So whilst it would have seen that in Q1 2020 markets fell by a record percentage before rebounding, it will not be able to factor in the cost of the coronavirus and lockdown and its impact on markets. Similarly, it is not able to consider ongoing Brexit woes, geo-political trade wars or the outcome of the US election in 2020.

Click here for the full article and to access more about the flexibility of the Architas Blended Range by clicking on the box below.

Read Guide Here

Read More

Continue Reading

Hot Stories